Ella represents venture-backed emerging growth technology companies across the full-spectrum of their corporate activities, including formation, venture capital financings and other private placements, public offerings, 1934 Act reporting, acquisitions, and other general corporate matters. She also counsels funds on their investments in these emerging growth technology companies. Her clients have included venture-backed companies primarily in the biotechnology, biopharmaceutical and medical devices sectors, as well as other technology-based companies.
Yale Law School, J.D. 1984
Rutgers University, B.A., Economics, summa cum laude
Phi Beta Kappa; Omicron Delta Epsilon, The International Honor Society for Economics; Alpha Phi Omega, a national co-ed service fraternity
Rutgers Law School--Camden
Mar 2014 – Apr 2014
Mar 2015 - Apr 2015
Served as an adjunct professor at Rutgers Camden School of Law in the Spring terms of 2014 and 2015. Subjects included Business Planning and Structuring and negotiation venture capital financial transactions.
Represented Tekla Healthcare Investors and Tekla Life Sciences Investors, closed-end funds focused on investments in public and private healthcare companies, in connection with their investments in the Series E Preferred Stock financing of Sutro Biopharma, a clinical stage drug discovery company creating protein therapeutics for oncology and autoimmune disorders.